URGENT: This Altcoin Opportunity Won’t Wait – Act Now

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

K. Murugan Biography and Net Worth

SVP of Atara Biotherapeutics

K. Amar Murugan is the Senior Vice President, General Counsel at Atara Biotherapeutics Inc.

What is K. Amar Murugan's net worth?: The estimated net worth of K. Amar Murugan is at least $104,133.15 as of August 16th, 2023. Mr. Murugan owns 10,615 shares of Atara Biotherapeutics stock worth more than $104,133 as of December 18th. This net worth approximation does not reflect any other investments that Mr. Murugan may own. Additionally, Mr. Murugan receives a salary of $718,500.00 as SVP at Atara Biotherapeutics. Learn More about K. Amar Murugan's net worth.
How old is K. Amar Murugan?: Mr. Murugan is currently 48 years old. There are 2 older executives and no younger executives at Atara Biotherapeutics. Learn More on K. Amar Murugan's age.
What is K. Amar Murugan's salary?: As the SVP of Atara Biotherapeutics, Inc., Mr. Murugan earns $718,500.00 per year. Learn More on K. Amar Murugan's salary.
How do I contact K. Amar Murugan?: The corporate mailing address for Mr. Murugan and other Atara Biotherapeutics executives is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. Atara Biotherapeutics can also be reached via phone at (805) 623-4211 and via email at [email protected]. Learn More on K. Amar Murugan's contact information.
Has K. Amar Murugan been buying or selling shares of Atara Biotherapeutics?: K. Amar Murugan has not been actively trading shares of Atara Biotherapeutics within the last three months. Most recently, Amar Murugan sold 346 shares of the business's stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $41.25, for a transaction totalling $14,272.50. Following the completion of the sale, the executive vice president now directly owns 10,615 shares of the company's stock, valued at $437,868.75. Learn More on K. Amar Murugan's trading history.
Who are Atara Biotherapeutics' active insiders?: Atara Biotherapeutics' insider roster includes Isaac Ciechanover (CEO), Jakob Dupont (EVP), Matthew Fust (Director), Utpal Koppikar (CFO), K. Murugan (SVP), Joe Newell (Insider), Thomas Peterffy (Chairman), Pascal Touchon (CEO), and Kristin Yarema (Insider). Learn More on Atara Biotherapeutics' active insiders.
Are insiders buying or selling shares of Atara Biotherapeutics?: During the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 17,499 shares worth more than $204,878.87. The most recent insider tranaction occured on November, 18th when EVP Jill Henrich sold 1,000 shares worth more than $11,200.00. Insiders at Atara Biotherapeutics own 3.7% of the company. Learn More about insider trades at Atara Biotherapeutics.
Information on this page was last updated on 11/18/2024.

K. Amar Murugan Insider Trading History at Atara Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/16/2023	Sell	346	$41.25	$14,272.50	10,615
5/16/2023	Sell	335	$51.00	$17,085.00	10,837
3/2/2023	Sell	168	$90.75	$15,246.00	11,173
11/16/2022	Sell	144	$112.25	$16,164.00	5,103
8/16/2022	Sell	137	$125.75	$17,227.75	5,247
5/17/2022	Sell	128	$133.00	$17,024.00	5,349
11/16/2021	Sell	84	$428.00	$35,952.00
8/17/2021	Sell	83	$313.25	$25,999.75	3,586

K. Amar Murugan Buying and Selling Activity at Atara Biotherapeutics

Atara Biotherapeutics Company Overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $9.81

$9.68

$10.60

50 Day Range

MA: $10.65

$7.78

$14.26

2 Week Range

Now: $9.81

$6.50

$39.50

Volume

76,980 shs

Average Volume

104,688 shs

Market Capitalization

$56.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

>> Register for the Workshop Now

K. Murugan Biography and Net Worth

What is K. Amar Murugan's net worth?

How old is K. Amar Murugan?

What is K. Amar Murugan's salary?

How do I contact K. Amar Murugan?

Has K. Amar Murugan been buying or selling shares of Atara Biotherapeutics?

Who are Atara Biotherapeutics' active insiders?

Are insiders buying or selling shares of Atara Biotherapeutics?